COMP <GO>
ACHC vs JNJ // FREE CASH FLOW YIELD
Acadia Healthcare Company Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ACHC 2
— JNJ 11
▲ FREE CASH FLOW YIELD LEADER: JNJ
LAST: $29.96 (+1.70%) • MKT CAP: $2.74B
fcf-yield
-16.04%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACHC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACHC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.80% | 25.50% | -50.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -16.04% | 2.97% | -19.01 | JNJ | /fcf-yield <GO> |
| Operating Margin | -40.60% | 34.70% | -75.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -33.30% | 28.50% | -61.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.00% | 6.00% | -1.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.59 | -5.14 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | ACHC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 60.4 | -9.87 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.08 | -0.01 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 23.0x | -2.00 | ACHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.74B | $662.49B | -$659.75B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACHC REV | JNJ REV | ACHC GROSS % | JNJ GROSS % | ACHC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.31B | $94.19B | 44.0% | 67.9% | -$439.9M | $19.70B |
| FY 2024 | $3.15B | $88.82B | 44.0% | 69.1% | -$560.7M | $19.84B |
| FY 2023 | $2.93B | $85.16B | 44.0% | 44.0% | $330.5M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACHC // BETA 1.07
JNJ // BETA 1.08